Open, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study

Basit Öğe Kaydı
dc.contributor.authorEskiyurt N.
dc.contributor.authorIrdesel J.
dc.contributor.authorSepici V.
dc.contributor.authorUgurlu H.
dc.contributor.authorKirazli Y.
dc.contributor.authorArdiç F.
dc.contributor.authorBütün B.
dc.contributor.authorAkyüz G.
dc.contributor.authorCerrahoglu L.
dc.contributor.authorŞendur Ö.F.
dc.contributor.authorYalçin P.
dc.contributor.authorÖncel S.
dc.contributor.authorSaridogan M.
dc.contributor.authorSarpel T.
dc.contributor.authorTosun M.
dc.contributor.authorKutsal Y.G.
dc.contributor.authorŞenel K.
dc.contributor.authorGürsoy S.
dc.contributor.authorCantürk F.
dc.contributor.authorDemir H.
dc.contributor.authorÖzdener F.
dc.contributor.authorÖncel H.
dc.date.accessioned2019-10-26T21:56:02Z
dc.date.available2019-10-26T21:56:02Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (?80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.en_US
dc.identifier.doi10.4274/tod.29491
dc.identifier.endpage7en_US
dc.identifier.issn2146-3816
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.4274/tod.29491
dc.identifier.urihttps://hdl.handle.net/11454/19009
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGalenos Yayincilik,en_US
dc.relation.ispartofTurk Osteoporoz Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBisphosphonateen_US
dc.subjectIbandronateen_US
dc.subjectPatient preferenceen_US
dc.subjectPostmenopausal osteoporosisen_US
dc.titleOpen, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu